| Literature DB >> 31088818 |
Justine Serre1, David Buob2,3, Jean-Jacques Boffa1,3.
Abstract
Hydroxychloroquine (HCQ) is largely prescribed as an immunomodulator to prevent systemic diseases flares in patients with systemic lupus erythematous, rheumatoid arthritis, Sjogren's disease. Among reported side effects, HCQ can accumulate in lysosomes and induced phospholipidosis. Here, we report an HCQ-induced podocytopathy mimicking Fabry disease (FD). They share the same histological lesions: cytoplasmic vacuolisation of the podocytes and zebra bodies on light and electronic microscopy. FD has been ruled out by measuring enzymatic activity and genetic test. The persistence of proteinuria after immunological remission of a systemic disease treated with HCQ could suggest this HCQ-induced podocytopathy. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: pathology; proteinurea; renal system; unwanted effects/adverse reactions
Mesh:
Substances:
Year: 2019 PMID: 31088818 PMCID: PMC6536225 DOI: 10.1136/bcr-2018-228876
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X